Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2
No significant differences in PFS, OS, or best response rates were observed between IL-2 and T-VEC treatments. The choice of therapy may be influenced by factors such as availability, physician preference, and patient-specific considerations.
Authors
- Teresa Amaral (ORCID: https://orcid.org/0000-0002-3998-6730)
- Nina Müller (ORCID: https://orcid.org/0000-0003-3639-7110)
- Andrea Forschner (ORCID: https://orcid.org/0000-0002-6185-4945)
- Valentin Aebischer (ORCID: https://orcid.org/0009-0000-7040-4949)
- Markus Reitmajer (ORCID: https://orcid.org/0000-0002-7134-1043)
- Ulrike Leiter (ORCID: https://orcid.org/0000-0002-8019-1577)
- Lukas Flatz (ORCID: https://orcid.org/0000-0001-9683-8390)
- Lena Nanz
Institutions
- University of Tübingen (DE)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251324035
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05